NCT04103476View on ClinicalTrials.gov

Advancing Postmenopausal Preventive Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
AtherosclerosisCognitive Decline
Interventions
COMBINATION_PRODUCT

Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg

Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg

OTHER

Placebo

Placebo

Trial Locations (1)

90033

University of Southern California Atherosclerosis Research Unit, Los Angeles

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Southern California

OTHER